Vivitrol Reduces Recidivism Rates

//Vivitrol Reduces Recidivism Rates

Vivitrol Reduces Recidivism Rates

vivitrolRelapse prevention is an understudied area of addiction; keeping former drug users from returning to their drug of choice is of the utmost priority. Many alcoholics with a history of chronic relapse turn to drugs like antabuse as an extra level of protection. With the growing rates of prescription opioid and heroin abuse, a number of addicts have been prescribed Vivitrol ®

[extended-release naltrexone (XR-NTX)] and the drug has shown to be remarkably effective. Naltrexone is a opioid antagonist which has been proven as an effective relapse prevention aid; the drug blocks the effects of opioids in the brain, such as: euphoria, pain relief, sedation, physical dependence and cravings.

New research suggests that giving naltrexone to inmates in jail for opioid related offenses could be effective in reducing recidivism rates, Medical News Today reports. Traditionally, people imprisoned for heroin possession detox and are released without any measures of relapse prevention, which nine times out of ten results in recidivism.

A pilot study conducted by researchers at NYU Langone Medical Center found that prescribing inmates in New York City jails extended-release naltrexone resulted in a significant decline in relapse rates for a group of mostly heroin-dependent men after their release.

“There has been a lot of interest in Vivitrol ® as post-incarceration relapse prevention, but not much actual data,” said lead investigator Joshua D. Lee, MD, MSc, associate professor of Population Health and Medicine at NYU Langone. “This randomized trial was designed to examine the impact of the medication on relapse to heroin in the first few weeks after release from jail, and it showed substantial benefits.”

A month out of jail, 88 percent of participants in the control group relapsed (those who did not receive Vivitrol ® injections), but only 38 percent of those who were given Vivitrol ® relapsed, according to the report. The researchers found that those given Vivitrol ® prior to release were less likely to be re-incarcerated during the study period.

“Opioid disorders now have two FDA-approved and effective maintenance medications and one for relapse prevention,” the authors write. “Prisons and jails are ideal environments to offer these treatments and to promote their continued use in the community.”

The findings were published in the journal Addiction.

2018-04-05T06:44:53+00:00 April 18th, 2015|Uncategorized|0 Comments

Leave A Comment